Journal profile · Oncology
TUMORI
ISSN 0300-8916 · eISSN 2038-2529 · Wichtig Publishing Srl · ITALY · Bimonthly · Founded 1911
TUMORI: CAS Zone 4 · Medicine (2025 upgraded edition); subscription journal; APC about USD 4,150; review about 6 months (community reports); community-reported acceptance: about 75%; 61 articles in 2025; indexed in Scopus.
Scope
Aims, scope and focus
TUMORI is published by Wichtig Publishing Srl and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Breast Cancer Treatment Studies, Cancer Treatment and Pharmacology and Lung Cancer Treatments and Mutations, together about 19.6% of its articles. Its main subfields are Oncology. (generated from OpenAlex topic counts and CAS ranking data)
Tumori Journal is an international peer reviewed journal centred on cancer research and clinical practice in oncology, committed to providing autho...
From the journal's Aims & Scope
Research area (LetPub): Oncology
Main research topics OpenAlex counts of recent articles; shares are approximate
- Breast Cancer Treatment StudiesBiochemistry, Genetics and Molecular Biology7.6%
- Cancer Treatment and PharmacologyMedicine6.4%
- Lung Cancer Treatments and MutationsMedicine5.7%
- Sarcoma Diagnosis and TreatmentMedicine5.7%
- Colorectal Cancer Treatments and StudiesMedicine5.2%
- Lymphoma Diagnosis and TreatmentMedicine4.9%
- Global Cancer Incidence and ScreeningMedicine4.5%
- Breast Lesions and CarcinomasMedicine4.4%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
Database indexing
ScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- CiteScore 2026-06
- 4LetPub ·
- SJR 2026-06
- 0.57LetPub ·
- SNIP 2026-06
- 0.71LetPub ·
- h-index
- 49LetPub ·
- h-index
- 75OpenAlex ·
- i10-index
- 2,381OpenAlex ·
- 2-year mean citedness
- 1.11OpenAlex ·
- Share of gold OA articles
- 0%LetPub ·
Volume
- Articles per year
- 106LetPub ·
Articles by year OpenAlex count · 8,317 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 69 | 22 | 12 |
| 2025 | 61 | 19 | 56 |
| 2024 | 63 | 23 | 146 |
| 2023 | 48 | 26 | 242 |
| 2022 | 62 | 21 | 555 |
| 2021 | 137 | 44 | 891 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
- Average review time (community reports)
- about 6 monthsLetPub ·
- Average acceptance (community reports)
- 75%LetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Subscription journalLetPub
A subscription journal: articles are read by subscription or purchase, and authors usually pay no publication charge.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 4,150 / GBP 3,043 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Wichtig Publishing Srl
- Country or region
- ITALY
- Language
- English
- Frequency
- Bimonthly
- Founded
- 1911
- ISSN
- 0300-8916
- Electronic ISSN
- 2038-2529
- Official links
- Journal homepage ↗OpenAlex
FAQ
Frequently asked questions about TUMORI
What CAS zone is TUMORI in?
In the 2025 upgraded edition of the CAS Journal Ranking, TUMORI is in Zone 4 of Medicine, and in Zone 4 of the minor category Oncology. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
How long does peer review take at TUMORI?
Authors report an average review time of about 6 months; the community-reported acceptance is “about 75%”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index TUMORI?
According to LetPub and DOAJ records, TUMORI is indexed in Scopus.
Is TUMORI open access, and what is the APC?
TUMORI is a subscription journal. APC about USD 4,150.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .